Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2005-08-02
2005-08-02
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S604000, C514S585000, C514S596000, C514S352000, C514S354000, C514S529000, C424S009100, C564S052000, C530S350000
Reexamination Certificate
active
06924311
ABSTRACT:
The present invention relates to methods for elevating high density lipoprotein (HDL) plasma levels, decreasing the absorption of dietary cholesterol in the intestine, decreasing the plasma level of low density lipoprotein (LDL), and increasing the conversion of cholesterol to bile acids, utilizing LXRβ selective agonists, usually without elevating the plasma levels of triglycerides. Also provided are methods of using such agonists to treat metabolic diseases alone or in combination with other active agents. Also provided are methods for decreasing hyperglycemia and insulin resistance methods for treating type II diabetes, and methods for treating type II diabetes and reducing the cardiovascular complications of type II diabetes, utilizing an LXR agonist. Further provided are methods for treating obesity and methods for treating the complications of obesity including type II diabetes, cardiovascular disease, hyperlipidemia, and hypertension, administering an LXRα-selective antagonist.
REFERENCES:
patent: 5273995 (1993-12-01), Roth
patent: 5571696 (1996-11-01), Evans et al.
patent: 5607967 (1997-03-01), Friedman et al.
patent: 5639616 (1997-06-01), Liao et al.
patent: 5679518 (1997-10-01), Friedman et al.
patent: 5696233 (1997-12-01), Evans et al.
patent: 5710004 (1998-01-01), Evans et al.
patent: 5747661 (1998-05-01), Evans et al.
patent: 5869284 (1999-02-01), Cao et al.
patent: 5939322 (1999-08-01), Rodan et al.
patent: 6184215 (2001-02-01), Elias et al.
patent: 6277976 (2001-08-01), Enmark et al.
patent: 6316503 (2001-11-01), Li et al.
patent: 2002/0072073 (2002-06-01), Medina et al.
patent: 2002/0116731 (2002-08-01), Allen et al.
patent: 2002/0177602 (2002-11-01), Piper
patent: WO 95/13373 (1995-05-01), None
patent: WO 96/05300 (1996-02-01), None
patent: WO 96/21726 (1996-07-01), None
patent: WO 97/28137 (1997-08-01), None
patent: WO 98/32444 (1998-07-01), None
patent: WO 99/18124 (1999-04-01), None
patent: WO 99/27365 (1999-06-01), None
patent: WO 00/34461 (2000-06-01), None
patent: WO 00/37077 (2000-06-01), None
patent: WO 00/54759 (2000-09-01), None
patent: WO 00/66611 (2000-11-01), None
patent: WO 00/78972 (2000-12-01), None
patent: WO 01/03659 (2001-01-01), None
patent: WO 01/03705 (2001-01-01), None
patent: WO 01/15676 (2001-03-01), None
patent: WO 01/41704 (2001-06-01), None
patent: WO 01/60818 (2001-08-01), None
patent: WO 02/11708 (2002-02-01), None
patent: WO 02/24632 (2002-03-01), None
patent: WO 02/55657 (2002-07-01), None
patent: WO 2004/058175 (2004-07-01), None
Stulnig, Thomas M., et al. “Liver X Receptors Downregulate 11β-Hydroxysteroid Dehydrogenase Type 1 Expression and Activity”,Diabetes, (2002), 51:2426-2433.
Cao, Guoqing, et al. “Antidiabetic Action of a Liver X Receptor Agonist Mediated By Inhibition of Hepatic Gluconeogenesis”,The Journal of Biological Chemistry, (2000), 273(2):1131-1136.
Alberti. “Structural Characterisation of the Mouse Nuclear Oxysterol Receptor Genes LXRα and LXRβ” Gene 243:93-103 (2000).
Apfel. et al. “A Novel Orphan Receptor Specific for a Subset of Thyroid Hormone-Responsive Elements and Its Interaction with the Retinoid/Thyroid Hormone Receptor Subfamily” Mol. Cell. Biol. 14:7025-7035 (1994).
Auboeuf et al. “Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator-Activated Receptors and Liver X Receptor-α in Humans” Diabetes 46:1319-1327 (1997).
Chen, et al. “Evidence That the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor in db/db Mice” Cell 84:491-495 (1996).
Evans, et al. “Inhibition of Cholesteryl Ester Transfer Protein in Normocholesterolemic and Hypercholesterolemic Hamsters: Effects on HDL Subspecies. Quantity, and Apolipoprotein Distribution” J. Lipid Res. 35:1634-1645 (1994).
Gordon, et al. “High Density Lipoprotein As a Protective Factor Against Coronary Heart Disease” Am. I. Med. 62:707-714 (1977).
Havel et al. “Structure and Metabolism of Plasma Lipoproteins” inMetabolic Basis of Inherited Disease. 6thed. 1989 pp. 1129-1138.
Janowski. “Structural Requirements of Ligands for the Oxysterol Liver X Receptors LXRα and LXRβ” PNAS 96:266-271 (1999).
Kannel, et al. “Cholesterol in the Prediction of Atherosclerotic Disease” Ann. Internal Med. 90:85-91 (1979).
Knowler, et al. “Obesity in the Pima Indians: Its Magnitude and Relationship with Diabetes” Am. J. Clin. Nutr. 53:1543-1551 (1991).
Laffitte et al “LXRs Control Lipid-inducible Expression of the Apolipoprotein E Gene in Macrophages and Adipocytes” PNAS 98(2):507-512 (2001).
Merck Manual, 16thed. 1992 pp. 1039-1040.
Peet, et al. “Cholesterol and Bile Acid Metabolism Are Impaired in Mice Lacking the Nuclear Oxysterol Receptor LXRα” Cell 93:693-704 (1998).
Repa. “The Role of Orphan Nuclear Receptors in the Regulation of Cholesterol Homeostasis” Annu. Rev. Cell Dev. Biol. 16:459-81 (2000).
Repa et al. “Regulation of Mouse Sterol Regulatory Element-binding Protein-1c Gene (SREBP-1c) by Oxysterol Receptors, LXRα and LXRβ” Genes & Devel 14:2819-2830 (2000).
Repa et al. “Inhibition of Cholesterol Absorption and Regulation of ABC1-mediated Cholesterol Efflux by the RXR/LXR Heterodimer” Science 289:1524-1529 (2000).
Saito et al. “Frequent Association of Alternative Splicing of NER, A Nuclear Hormone Receptor Gene in Cancer Tissues” Oncogene 14:617-621 (1997).
Schultz et al. “Role of LXRs in Control of Lipogenesis” Genes & Development 14:2831-2838 (2000).
Seol et al. “Isolation of Proteins That Interact Specifically with the Retinoid X Receptor: Two Novel Orphan Receptors” Molec. Endo. 9:72-85 (1995).
Shinar et al“NER, A New Member of the Gene Family Encoding the Human Steroid Hormone Nuclear Receptor” Gene 147(2):273-276 (1994) (Abstract) at <http://www.ncbi.nlm.nih.gov> (visited Jan. 29, 2001).
Song et al. “Ubiquitous Receptor: A Receptor That Modulates Gene Activation by Retinoic Acid and Thyroid Hormone Receptors” PNAS 91:10809-10813 (1994).
Teboul “OR-1, A Member of the Nuclear Receptor Superfamily That Interacts with the 9-cis-retinoic Acid Receptor” PNAS 92:2096-2100 (1995).
Tobin. “Cross-Talk Between Fatty Acid and Cholesterol Metabolism Mediated by Liver X Receptor-α” Molecular Endocrinology 14(5):741-752 (2000).
Tobin et al. “Liver X Receptors as Insulin-mediating Factors in Fatty Acid and Cholesterol Biosynthesis” J. Biol. Chem. 277(12):10691-10697 (2002).
Venkateswaran et al. “Control of Cellular Cholesterol Efflux by the Nuclear Oxysterol Receptor LXRα” PNAS 97(22):12097-12102 (2000).
Willy, et al. “LXR, A Nuclear Receptor That Defines a Distinct Retinoid Response Pathway” Genes Dev. 9:1033-1045 (1995).
Bischoff Eric D.
Schulman Ira G.
Tangirala Rajendra K.
Kam Chih-Min
Townsend and Townsend / and Crew LLP
Weber Jon
X-Ceptor Therapeutics, Inc.
LandOfFree
Methods for affecting various diseases utilizing LXR compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for affecting various diseases utilizing LXR compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for affecting various diseases utilizing LXR compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3512650